ATRC-101 is a monoclonal antibody commercialized by Atreca, with a leading Phase I program in Esophageal Squamous Cell Carcinoma (ESCC). According to Globaldata, it is involved in 4 clinical trials, of which 1 is ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of ATRC-101’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for ATRC-101 is expected to reach an annual total of $119 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
ATRC-101 is under development for the treatment of solid tumors including non-small cell lung adenocarcinoma, acral melanoma, colorectal cancer, epithelial ovarian cancer, hepatocellular carcinoma, triple negative breast cancer, head and neck cancer squamous cell carcinoma, esophageal squamous cell carcinoma (ESCC), transitional cell carcinoma (urothelial cell carcinoma) and breast adenocarcinoma. It is administered as intravenous infusion. The drug candidate is an engineered, fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally-occurring human antibody developed through driver antigen engagement program based on immune repertoire capture (IRC) technology. ATRC-101 targets ribonucleoprotein (RNP) complex, it binds to a polyadenylate-binding protein (PABP-1) within its target RNP complex.
Atreca is a biotechnology company. It develops novel therapies based on the human immune response. The company develops proprietary immune repertoire capture technology that act as an engine for the discovery and development of antibody based therapeutics, diagnostics, vaccines and research reagents. Its technology has partnerships with pharmaceutical companies, academic institutions, non-profit foundations and governmental entities. Its pipeline products are intended for the treatment of breast tumor, lung tumor, colon tumor and other solid tumors. Atreca is headquartered in Redwood City, California, the US.
The operating loss of the company was US$98.7 million in FY2022, compared to an operating loss of US$110.3 million in FY2021. The net loss of the company was US$97.2 million in FY2022, compared to a net loss of US$109.3 million in FY2021.
For a complete picture of ATRC-101’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.